Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308584 | 0.81 | ALDH1A1 (0.44) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL623186 | 0.79 | GRM6 (0.50) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL9486405 | 0.77 | ALDH1A1 (0.41) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL9487470 | 0.77 | ALDH1A1 (0.41) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL12111251 | 0.77 | ALDH1A1 (0.50) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL1720717 | 0.74 | ALDH1A1 (0.46) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL1621985 | 0.74 | ALDH1A1 (0.49) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL11064868 | 0.73 | BPTF (0.48) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL10298787 | 0.73 | GRM6 (0.45) | GRM6ALDH1A1HSD17B10MAPK1TSHR | |
| SCHEMBL1622057 | 0.73 | ADORA2A (0.48) | GRM6ALDH1A1HSD17B10MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4134083-A | — | — | None | — | — | JP | disclosed |
| EP-4719369-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4714456-A2 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025151311-A1 | NICOTINAMIDE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024254161-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | CELLORAM INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-118541359-A | Inhibitors of molluscum contagiosum infection and methods of use thereof | 宾夕法尼亚大学董事会 | 2024-08-23 | — | — | CN | disclosed |
| EP-4408833-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-112538078-B | Polycyclic compound for inhibiting DHX33 helicase | 成都开悦生命科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-4831013-A | BENZODIAZEPINE RECEPTOR ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| WO-1988002370-A1 | 2-SUBSTITUTED-E-FUSED-[1,2,4]TRIAZOLO[1,5-C]PYRIMIDINES PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CIBA-GEIGY AG (CH) | 1988-04-07 | — | — | WO | disclosed |
| EP-0263071-A1 | 2-Substituted-e-fused-[1,2,4]-triazolo[1,5-c] pyrimidines, pharmaceutical compositions, and uses thereof | CIBA-GEIGY AG (CH) | 1988-04-06 | — | — | EP | disclosed |
| US-4692461-A | PLANT PROTECTION | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| EP-0224140-A1 | Thienyl urea derivatives | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0217748-A2 | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof | CIBA-GEIGY AG (CH) | 1987-04-08 | — | — | EP | disclosed |
| EP-0062200-B1 | DISAZO DYESTUFFS | BASF Aktiengesellschaft (DE) | 1985-01-23 | — | — | EP | disclosed |
| EP-0062200-A1 | Disazo dyestuffs | BASF Aktiengesellschaft (DE) | 1982-10-13 | — | — | EP | disclosed |
| EP-0037465-A2 | Amino azo compounds | BASF Aktiengesellschaft (DE) | 1981-10-14 | — | — | EP | disclosed |
| US-3953468-A | ALLERGIES | THE UPJOHN COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | DHX36, DDX21, DDX3X | GRM6 2421/4885ALDH1A1 1988/4885HSD17B10 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.